Clinical significance of MMP-2, MMP-9 and HIF-1α expression in thyroid micropapillary cancer

Journal of the Korean Surgical Society

Volumn 78, Issue 3, 2010, Pages 157-164

  Choi, Jae Young ^a   Bae, Ja Seong ^a   Ki, Young Ae ^b   Chang, Eun Deok ^a   Cho, Hang Joo ^a   Kim, Ki Hwan ^a   Ahn, Chang Hyeok ^a   Park, Woo Chan ^a   Kim, Jeong Soo ^a  

^a Uijeongbu St Mary's Hospital   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

HIF 1 ; MMP 2; MMP 9; Papillary microcarcinoma; Thyroid carcinoma

Indexed keywords

EID: 79960155250     PISSN: 12260053     EISSN: 20930488     Source Type: Journal    
DOI: 10.4174/jkss.2010.78.3.157     Document Type: Article

References (30)

1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-7.
2. Ministry of Health and Welfare. Annual Report of the Korea Central Cancer Registry 2002. 2007.
3. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-11. (Pubitemid 36173719)
4. Hodgson NC, Button J, Solorzano CC. Thyroid cancer: is the incidence still increasing? Ann Surg Oncol 2004;11:1093-7. (Pubitemid 40486656)
5. Choi YJ, Park YL, Koh JH. Prevalence of thyroid cancer at a medical screening center: pathological features of screen-detected thyroid carcinomas. Yonsei Med J 2008;49:748-56.
6. Beasley NJ, Lee J, Eski S, Walfish P, Witterick I, Freeman JL. Impact of nodal metastases on prognosis in patients with well-differentiated thyroid cancer. Arch Otolaryngol Head Neck Surg 2002;128:825-8. (Pubitemid 34755316)
7. Kilicarslan AB, Ogus M, Arici C, Pestereli HE, Cakir M, Karpuzoglu G. Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas. APMIS 2003;111:439-43. (Pubitemid 36560544)
8. Scarpino S, Cancellario d'Alena F, Di Napoli A, Pasquini A, Marzullo A, Ruco LP. Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J Pathol 2004;202:352-8. (Pubitemid 38325245)
9. von Wasielewski R, Rhein A, Werner M, Scheumann GF, Dralle H, Potter E, et al. Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res 1997;57:2501-7. (Pubitemid 27255913)
10. Klein M, Picard E, Vignaud JM, Marie B, Bresler L, Toussaint B, et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol 1999;161:41-9. (Pubitemid 29170190)
11. Hay ID, Grant CS, van Heerden JA, Goellner JR, Ebersold JR, Bergstralh EJ. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery 1992; 112:1139-46; discussion 46-7.
12. Baudin E, Travagli JP, Ropers J, Mancusi F, Bruno-Bossio G, Caillou B, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 1998;83:553-9. (Pubitemid 28354512)
13. Manole D, Schildknecht B, Gosnell B, Adams E, Derwahl M. Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. J Clin Endocrinol Metab 2001;86:1072-7. (Pubitemid 32322984)
14. Lee ML, Chen GG, Vlantis AC, Tse GM, Leung BC, van Hasselt CA. Induction of thyroid papillary carcinoma cell proliferation by estrogen is associated with an altered expression of Bcl-xL. Cancer J 2005;11:113-21. (Pubitemid 44698822)
15. Zeng Q, Chen GG, Vlantis AC, van Hasselt CA. Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway. Cell Prolif 2007;40:921-35. (Pubitemid 350135201)
16. Cho MA, Lee MK, Nam KH, Chung WY, Park CS, Lee JH, et al. Expression and role of estrogen receptor alpha and beta in medullary thyroid carcinoma: different roles in cancer growth and apoptosis. J Endocrinol 2007;195:255-63. (Pubitemid 350143105)
17. Yane K, Kitahori Y, Konishi N, Okaichi K, Ohnishi T, Miyahara H, et al. Expression of the estrogen receptor in human thyroid neoplasms. Cancer Lett 1994;84:59-66. (Pubitemid 24260283)
18. Egawa C, Miyoshi Y, Iwao K, Shiba E, Noguchi S. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in normal and malignant thyroid tissues by real-time polymerase chain reaction. Oncology 2001; 61:293-8. (Pubitemid 33135838)
19. Hirohashi S, Kanai Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci 2003;94:575-81. (Pubitemid 36975010)
20. Kapran Y, Ozbey N, Molvalilar S, Sencer E, Dizdaroglu F, Ozarmagan S. Immunohistochemical detection of E-cadherin, alpha- and beta-catenins in papillary thyroid carcinoma. J Endocrinol Invest 2002;25:578-85. (Pubitemid 34784736)
21. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000;10:415-33. (Pubitemid 32181912)
22. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000;2:252-7. (Pubitemid 32223594)
23. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-49. (Pubitemid 30123793)
24. Yeh MW, Rougier JP, Park JW, Duh QY, Wong M, Werb Z, et al. Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A. Endocr Relat Cancer 2006;13:1173-83. (Pubitemid 46212571)
25. Tian X, Cong M, Zhou W, Zhu J, Liu Q. Relationship between protein expression of VEGF-C, MMP-2 and lymph node metastasis in papillary thyroid cancer. J Int Med Res 2008; 36:699-703.
26. Jiang JB, Li XM, Zhang WD, Zhu M, Shou NH. Relationship of vascular endothelial growth factor-C and lymphangiogenesis with the development and prognosis of colon cancer. Zhonghua Wei Chang Wai Ke Za Zhi 2005;8:516-9.
27. Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R, et al. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 2001;61: 2256-60. (Pubitemid 32692056)
28. Lennard CM, Patel A, Wilson J, Reinhardt B, Tuman C, Fenton C, et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 2001;129:552-8. (Pubitemid 32374986)
29. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359:31-42. (Pubitemid 351931094)
30. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62-7. (Pubitemid 34297081)